



BioLineRx to Report Third Quarter 2012 Results on November 14, 2012

November 5, 2012

Management to hold conference call at 9:00 a.m. EST

JERUSALEM--(BUSINESS WIRE)--Nov. 5, 2012-- BioLineRx Ltd. (NASDAQ: [BLRX](#)) (TASE: [BLRX](#)), a biopharmaceutical development company, announced today that it will release its unaudited financial results for the quarter ended September 30, 2012 on Wednesday, November 14, 2012, before the U.S. markets open.

The Company will host a conference call on Wednesday, November 14 at 9:00 a.m. EST featuring remarks by Kinneret Savitsky, Ph.D., CEO of BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of BioLineRx. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website, www.bioglinerx.com, and www.kcsa.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-888-407-2553 from the U.S. or +972-3-918-0610 internationally.

A replay of the conference call will be available approximately two hours after completion of the live conference call at www.bioglinerx.com or www.kcsa.com. A dial-in replay of the call will be available until November 17, 2012; please dial 1-877-456-0009 from the U.S. or +972-3-9255925 internationally.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of six clinical stage candidates: BL-1020 for schizophrenia is currently undergoing a Phase II/III study; BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Icaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development, BL-7040 for treating inflammatory bowel disease (IBD) currently undergoing a Phase II trial, and BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers has completed Phase I. In addition, BioLineRx has nine products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase III) and commercialization. For more information on BioLineRx, please visit www.bioglinerx.com.

Source: BioLineRx Ltd.

KCSA Strategic Communications
Garth Russell, 1-212-896-1250
grussell@kcsa.com

or

Todd Fromer, 1-212-896-1215
tfromer@kcsa.com

or

Tsipi Haitovsky, Public Relations
+972-52-598-9892
tsipih@netvision.net.il